- Poster presentation
- Open Access
Immunological changes after one year of specific immunotherapy with Pru p 3
© Gomez et al; licensee BioMed Central Ltd. 2015
- Published: 30 March 2015
- Skin Prick Test
- Food Challenge
- Double Blind Placebo
In Southern Europe Pru p3 is the primary sensitizer of plants fruit and responsible for severe reactions. Specific immunotherapy (SIT) brings a new perspective to treat anaphylactic patients. There is a lack of knowledge regarding immunological response that includes changes in the basophil activation and antibody production during IT. We aimed to analyse early changes in the basophil response to Pru p 3 and another related allergen (Ara h 9) during the first year of sublingual immunotherapy (SLIT).
Forty-six peach allergic patients confirmed as positive by skin prick test, ImmunoCAP IgE and/or a double blind placebo control food challenge. Basophil reactivity was determined by the basophil activation test (BAT) with Pru p 3 and Ara h 9 at three concentrations, 1, 0.1 and 0.01 µg/ml, before and after 1, 4 and 12 months of SLIT. Levels of specific IgE and IgG4 were measured at the same time intervals.
From the total number of cases 45% had anaphylaxis and 55% urticaria and/or angioedema. Sensitisation to other plants appeared in 82,6% and to pollens in 69,5%. After the first month of treatment, 28% patients showed an increase in the basophil reactivity to Pru p 3, 36% patients showed no changesin their reactivity and 36% presented a decreased reactivity to Pru p 3. Similar results were obtained for Ara h 9. We observed a decrease in IgE levels and an increase of IgG4 in the group of patients that completed a year of SIT.
Preliminary results disclosed that soon after the first years of SLIT, patients showed a different behaviour in the basophil reactivity with good correlation in the response to Pru p3 and Ara h 9.After one year of SIT we observed a decrease of IgE and an increase of IgG4.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.